NCI-2022-06813

A Phase 1/2, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, andPreliminary Antitumor Activity of NDI-101150 Administered as Monotherapy or in Combination withPembrolizumab in Patients with Solid Tumors

This Phase 1/2 open-label study is looking at a new drug called NDI-101150 in people with solid tumors to see if it's safe and if it works against cancer. They'll give NDI-101150 alone or with another drug called pembrolizumab, which helps the immune system fight cancer. The goal is to check if NDI-101150 is safe, how it moves through the body, and if it can help shrink tumors, possibly working even better when combined with pembrolizumab.

Phase 1/2: A study that assesses the safety, effectiveness, and how well the treatment works

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05128487

Clinical Trial Site: Columbia

To see all available clinical trials click here.